In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease

被引：16
作者：
Ridder, Dirk A. [1 ]
Schwaninger, Markus [1 ]
机构：
[1] Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany
来源：
EXPERIMENTAL NEUROLOGY | 2012年 / 238卷 / 02期
关键词：
MPTP; MPP+; Glitazones; Oxidative stress; PPAR gamma; ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; PROGRAMMED CELL-DEATH; PPAR-GAMMA; MOUSE MODEL; AGONIST PIOGLITAZONE; ALZHEIMERS-DISEASE; MITOCHONDRIAL DYSFUNCTION; INFLAMMATORY RESPONSE;
D O I：
10.1016/j.expneurol.2012.08.012
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
The oral antidiabetic thiazolidinediones exert protective effects in models of Parkinson's disease and other neurological diseases. While the antidiabetic effect is due to activation of PPAR gamma, the mechanisms underlying the neuroprotection are more controversial. It may involve activation of PPAR gamma blocking inflammation and apoptosis. However, new evidence suggests an antioxidative PPAR gamma-independent action. Here we discuss recent data on the mode of action of TZDs in models of PD and their implication for the translation into the clinic. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码：133 / 137
页数：5
相关论文
共 61 条
  • [1] PPARγ is required for placental, cardiac, and adipose tissue development
    Barak, Y
    Nelson, MC
    Ong, ES
    Jones, YZ
    Ruiz-Lozano, P
    Chien, KR
    Koder, A
    Evans, RM
    [J]. MOLECULAR CELL, 1999, 4 (04) : 585 - 595
  • [2] Animal models of Parkinson's disease
    Blandini, Fabio
    Armentero, Marie-Therese
    [J]. FEBS JOURNAL, 2012, 279 (07) : 1156 - 1166
  • [3] Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
    Breidert, T
    Callebert, J
    Heneka, MT
    Landreth, G
    Launay, JM
    Hirsch, EC
    [J]. JOURNAL OF NEUROCHEMISTRY, 2002, 82 (03) : 615 - 624
  • [4] Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
    Carta, Anna R.
    Pisanu, Augusta
    Carboni, Ezio
    [J]. PARKINSONS DISEASE, 2011, 2011
  • [5] Glutamate, excitotoxicity, and programmed cell death in parkinson disease
    Caudle, W. Michael
    Zhang, Jing
    [J]. EXPERIMENTAL NEUROLOGY, 2009, 220 (02) : 230 - 233
  • [6] PPAR: a therapeutic target in Parkinson's disease
    Chaturvedi, Rajnish K.
    Beal, M. Flint
    [J]. JOURNAL OF NEUROCHEMISTRY, 2008, 106 (02) : 506 - 518
  • [7] PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
    Chawla, A
    Barak, Y
    Nagy, L
    Liao, D
    Tontonoz, P
    Evans, RM
    [J]. NATURE MEDICINE, 2001, 7 (01) : 48 - 52
  • [8] Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe
    Colca, JR
    McDonald, WG
    Waldon, DJ
    Leone, JW
    Lull, JM
    Bannow, CA
    Lund, ET
    Mathews, WR
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (02): : E252 - E260
  • [9] Collino Massimo, 2008, Ther Adv Cardiovasc Dis, V2, P179, DOI 10.1177/1753944708090924
  • [10] Mitochondrial kinases in Parkinson's disease: Converging insights from neurotoxin and genetic models
    Dagda, Ruben K.
    Zhu, Jianhui
    Chu, Charleen T.
    [J]. MITOCHONDRION, 2009, 9 (05) : 289 - 298
1234567